We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021

A new study revealing how antibodies against the SARS-CoV-2 virus can vary among recipients of COVID-19 vaccines and naturally infected individuals was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. More...

In the new study, a research group at the University Hospitals Cleveland Medical Center (Cleveland, OH, USA) set out to define differences in antibodies against SARS-CoV-2 among vaccinated and unvaccinated individuals.

The scientists tested for antibodies against the SARS-CoV-2 spike protein, receptor-binding domain (RBD), nucleocapsid protein, and the spike protein’s S1 and S2 subunits in three study groups: 33 fully vaccinated healthcare workers, 52 healthcare workers who had recovered from natural infection, and 34 patients with active infections. The test results revealed that the fully vaccinated individuals had an average of 50-fold higher antibody levels than naturally infected, unvaccinated individuals. Antibodies from the vaccinated group also reacted far more strongly to the RBD and S1 viral antigens, suggesting that antibodies against these proteins could be the best targets for tests developed in the future.

Follow-up studies that profile changes in SARS-CoV-2 antibodies over time for vaccinated individuals and those with breakthrough infections could yield further insights, according to Xiaochun Zhang, MD, PhD, of University Hospitals Cleveland Medical Center. “With the third dose of mRNA vaccine on the horizon, this type of study may help identify practical indicator in optimizing booster-dose planning if an association between antibody level and infection risk is proved,” she said.

Related Links:
University Hospitals Cleveland Medical Center 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.